Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Jensen, M. D.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Jensen, M. D.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Adipose tissue as an endocrine organ: implications of its distribution on free fatty acid metabolism

Michael D. Jensen*

Endocrine Research Unit, Mayo College of Medicine, 5-194 Joseph, Mayo Clinic, Rochester, MN 55905, USA

* Corresponding author. Tel: +1 507 255 6515; fax: +1 507 255 4828. E-mail address: jensen{at}mayo.edu

Free fatty acids (FFAs) are the main circulating lipid fuel in the post-absorptive state. Elevated plasma FFA concentrations are associated with increased endogenous glucose production rates and insulin resistance in skeletal muscle, whereas long-term exposure of pancreatic ß-cells to elevated FFA impairs insulin secretion, with a consequently increased risk of developing type 2 diabetes. A range of adverse changes occur in the vascular endothelium in response to elevation of plasma FFA concentrations that are similar to key early steps in atherogenesis. These include reduced endothelium-dependent vasodilatation and increased expression of adhesion molecules. We have found that the majority of systemic plasma FFAs originate from upper-body subcutaneous fat, with lesser contributions from leg fat and intra-abdominal adipocytes, even in persons with abdominal obesity. However, systemic FFA concentrations correlate positively with visceral fat, so that FFA release from visceral depots appears to serve as a marker of systemic insulin resistance. In addition, the secretion of a range of bioactive substances from intra-abdominal adipocytes (adipokines) is disturbed, with potentially deleterious consequences for metabolism and overall cardiometabolic risk. Interventions that reduce circulating FFA, either due to or independently of weight loss, are likely to improve insulin sensitivity, ß-cell function, and cardiovascular risk. Weight loss in overweight or obese patients would have the additional benefit of reducing intra-abdominal adiposity and tending to correct the pathologically altered adipokine secretion associated with abdominal obesity.

Key Words: Abdominal obesity • Cardiovascular risk • Dyslipidaemia • Free fatty acids • Insulin resistance • Lipolysis


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
A. Peter, C. Weigert, H. Staiger, K. Rittig, A. Cegan, P. Lutz, F. Machicao, H.-U. Haring, and E. Schleicher
Induction of stearoyl-CoA desaturase protects human arterial endothelial cells against lipotoxicity
Am J Physiol Endocrinol Metab, August 1, 2008; 295(2): E339 - E349.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.